The Oncology Connection

(3)

Erdafitinib for the Treatment of Urothelial Carcinoma

Donald C Moore Donald C Moore

Erdafitinib (Balversa®, Janssen Products, LP) is a novel fibroblast growth factor receptor (FGFR) inhibitor recently approved by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with a susceptible FGFR3 or FGFR2 genetic alteration who have ...

Read more

Enfortumab vedotin-ejfv (PADCEV)

Grashma Vadakkel, PharmD Grashma Vadakkel, PharmD

Bladder cancer is the sixth most common cancer in the United States. Patients with locally advanced or metastatic disease have poor long-term survival, especially those who have progressed after chemotherapy and immunotherapy. A new agent, enfortumab vedotin-ejfv (PADCEV, Astellas Pharma US, Inc.), ...

Read more

HPV-Associated head and neck cancer: Racial Disparities in Outcomes

Faith Mutale, MSN, CRNP Faith Mutale, MSN, CRNP

Although risk factors for squamous-cell cancer of the head and neck (SCCHN) have been identified (e.g., tobacco use, alcohol use, human papilloma virus [HPV] infection), the impact of social determinants of health (SDH) in patients with SCCHN has been poorly characterized. Moreover, ...

Read more